Evidence map›Paper›PMID 33673859›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

TP53 drives abscopal effect by secretion of senescence-associated molecular signals in non-small cell lung cancer.

Anna Tesei, Chiara Arienti, Gianluca Bossi, Spartaco Santi, Ilaria De Santis, Alessandro Bevilacqua, Michele Zanoni, Sara Pignatta, Michela Cortesi, Alice Zamagni and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Aging and lung diseases: Unraveling mechanisms and therapeutic targets.Chinese medical journal pulmonary and critical care medicine · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Anna Tesei *Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. anna.tesei@irst.emr.it.
Chiara Arienti *Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. chiara.arienti@irst.emr.it.
Gianluca Bossi *Oncogenomic and Epigenetic Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy. gianluca.bossi@ifo.gov.it.
Spartaco SantiCNR Institute of Molecular Genetics "Luigi Luca Cavalli-Sforza", Bologna, Italy.
Ilaria De SantisDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, I-40138, Bologna, Emilia Romagna, Italy.
Alessandro BevilacquaDepartment of Computer Science & Engineering (DISI), University of Bologna, Bologna, Italy.
Michele ZanoniBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Sara PignattaBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Michela CortesiBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Alice ZamagniBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Gianluca StorciDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Massimiliano BonafèDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Anna SarnelliMedical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Antonino RomeoRadiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Carola CavalloLaboratorio RAMSES, Rizzoli Research, Innovation & Technology Department (RIT), IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Armando BartolazziPathology Research laboratory, Sant'Andrea Hospital, Rome, Italy.
Stefania RossiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Antonella SorianiLaboratory of Medical Physics and Expert Systems, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Lidia Strigari *Department of Medical Physics, IRCCS University Hospital of Bologna, via Massarenti 9, 40138, Bologna, Italy. lidia.strigari@aosp.bo.it.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bologna · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITCTO Andrea Alesini · ITIstituto di Genetica Molecolare · ITIstituto Ortopedico Rizzoli · ITIstituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent developments in abscopal effect strongly support the use of radiotherapy for the treatment of metastatic disease. However, deeper understanding of the molecular mechanisms underlying the abscopal effect are required to best benefit a larger proportion of patients with metastasis. Several groups including ours, reported the involvement of wild-type (wt) p53 in radiation-induced abscopal effects, however very little is known on the role of wtp53 dependent molecular mechanisms.

methodsWe investigated through in vivo and in vitro approaches how wtp53 orchestrates radiation-induced abscopal effects. Wtp53 bearing (A549) and p53-null (H1299) NSCLC lines were xenotransplanted in nude mice, and cultured in 2D monolayers and 3D tumor spheroids. Extracellular vesicles (EVs) were isolated from medium cell culture by ultracentrifugation protocol followed by Nanoparticle Tracking Analysis. Gene expression was evaluated by RT-Real Time, digital qRT-PCR, and dot blot technique. Protein levels were determined by immunohistochemistry, confocal anlysis, western blot techniques, and immunoassay.

resultsWe demonstrated that single high-dose irradiation (20 Gy) induces significant tumor growth inhibition in contralateral non-irradiated (NIR) A549 xenograft tumors but not in NIR p53-null H1299 or p53-silenced A549 (A549sh/p53) xenografts. We further demonstrates that irradiation of A549 cells in vitro induces a senescence-associated secretory phenotype (SASP) producing extracellular vesicles (EVs) expressing CD63 and carrying DNA:RNA hybrids and LINE-1 retrotransposon. IR-A549 EVs also hamper the colony-forming capability of recipient NIR A549 cells, induce senescent phenotype, nuclear expression of DNA:RNA hybrids, and M1 macrophage polarization.

conclusionsIn our models, we demonstrate that high radiation dose in wtp53 tumors induce the onset of SASP and secretion of CD63+ EVs loaded with DNA:RNA hybrids and LINE-1 retrotransposons that convey senescence messages out of the irradiation field triggering abscopal effect in NIR tumors.

Indexed as

A549 CellsAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCellular SenescenceFemaleHeterograftsHumansLung NeoplasmsMiceMice, NudeRAW 264.7 CellsTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53Abscopal effectCellular senescenceDNA:RNA hybridsExtracellular vesiclesNon-small cell lung cancerRetrotransposonTP53

Identifiers

PMID33673859
PMCPMC7934399
OpenAlexW3111389306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.